Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

Palacio-Portilla, Enrique Jesús; Roquer, Jaume; Amaro, Sergio; Arenillas, Juan F.; Ayo-Martín, Óscar; Castellanos, M.; Freijo, María del Mar; Fuentes Gimeno, Blanca Eulalia; García-Pastor, Andrés; Gomis González, Maria, 1988-; Gómez-Choco, Manuel; López-Cancio, Elena; Martínez-Sánchez, Patricia; Morales, A.; Rodríguez-Yáñez, Manuel; Segura, Tomás; Serena, Joaquín; Vivancos-Mora, José; Leciñana, María Alonso de; Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología

Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia. Development: We performed a systematic review to evaluate the main aspects of the management of dyslipidaemias in primary...

Descripción completa

Detalles Bibliográficos
Autores:	Palacio-Portilla, Enrique Jesús, Roquer, Jaume, Amaro, Sergio, Arenillas, Juan F., Ayo-Martín, Óscar, Castellanos, M., Freijo, María del Mar, Fuentes Gimeno, Blanca Eulalia, García-Pastor, Andrés, Gomis González, Maria, 1988-, Gómez-Choco, Manuel, López-Cancio, Elena, Martínez-Sánchez, Patricia, Morales, A., Rodríguez-Yáñez, Manuel, Segura, Tomás, Serena, Joaquín, Vivancos-Mora, José, Leciñana, María Alonso de, Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2022
País:	España
Institución:	Universitat Pompeu Fabra
Repositorio:	Repositorio Digital de la UPF
OAI Identifier:	oai:repositori.upf.edu:10230/54337
Acceso en línea:	http://hdl.handle.net/10230/54337 http://dx.doi.org/10.1016/j.nrleng.2020.07.021
Access Level:	acceso abierto
Palabra clave:	Dislipidemia Dyslipidaemia Estatinas Ictus LDL cholesterol LDL colesterol Prevención Prevention Statins Stroke

id	ES_159161ebfa61c7ee92e2f2f3a6eb6209
oai_identifier_str	oai:repositori.upf.edu:10230/54337
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of NeurologyDislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de NeurologíaPalacio-Portilla, Enrique JesúsRoquer, JaumeAmaro, SergioArenillas, Juan F.Ayo-Martín, ÓscarCastellanos, M.Freijo, María del MarFuentes Gimeno, Blanca EulaliaGarcía-Pastor, AndrésGomis González, Maria, 1988-Gómez-Choco, ManuelLópez-Cancio, ElenaMartínez-Sánchez, PatriciaMorales, A.Rodríguez-Yáñez, ManuelSegura, TomásSerena, JoaquínVivancos-Mora, JoséLeciñana, María Alonso deGrupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de NeurologíaDislipidemiaDyslipidaemiaEstatinasIctusLDL cholesterolLDL colesterolPrevenciónPreventionStatinsStrokeObjective: We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia. Development: We performed a systematic review to evaluate the main aspects of the management of dyslipidaemias in primary and secondary stroke prevention and establish a series of recommendations. Conclusions: In primary prevention, the patient's vascular risk should be determined in order to define target values for low-density lipoprotein cholesterol. In secondary prevention after an atherothrombotic stroke, a target value <55 mg/dL is recommended; in non-atherothombotic ischaemic strokes, given the unclear relationship with dyslipidaemia, target value should be established according to the vascular risk group of each patient. In both primary and secondary prevention, statins are the drugs of first choice, and ezetimibe and/or PCSK9 inhibitors may be added in patients not achieving the target value.Objetivo: Actualizar las recomendaciones de la Sociedad Española de Neurología para la prevención del ictus, tanto primaria como secundaria en pacientes con dislipidemia. Desarrollo: Se ha realizado una revisión sistemática en Pubmed evaluando los principales aspectos relacionados con el manejo de las dislipidemias en la prevención primaria y secundaria del ictus, elaborándose una serie de recomendaciones relacionadas con los mismos. Conclusiones: En prevención primaria se recomienda determinar el riesgo vascular del paciente con el fin de definir los objetivos de LDLc. En prevención secundaria tras un ictus de origen aterotrombótico se recomienda un objetivo de LDLc < 55 mg/dl, mientras que en ictus isquémicos de origen no aterotrombótico dado que su relación con dislipidemias es incierta se establecerán los objetivos en base al grupo de riesgo vascular de cada paciente. Tanto en prevención primaria como secundaria las estatinas son los fármacos de primera elección, pudiendo asociarse ezetimiba y/o inhibidores de PCSK9 en aquellos casos que no alcancen los objetivos terapéuticos.Elsevier202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/54337http://dx.doi.org/10.1016/j.nrleng.2020.07.021reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésNeurologia (Engl Ed). 2022 Jan-Feb;37(1):61-72. DOI: 10.1016/j.nrleng.2020.07.021© 2020 Sociedad Española de Neurología. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/543372026-06-12T07:21:37Z
dc.title.none.fl_str_mv	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
title	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
spellingShingle	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology Palacio-Portilla, Enrique Jesús Dislipidemia Dyslipidaemia Estatinas Ictus LDL cholesterol LDL colesterol Prevención Prevention Statins Stroke
title_short	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
title_full	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
title_fullStr	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
title_full_unstemmed	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
title_sort	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
dc.creator.none.fl_str_mv	Palacio-Portilla, Enrique Jesús Roquer, Jaume Amaro, Sergio Arenillas, Juan F. Ayo-Martín, Óscar Castellanos, M. Freijo, María del Mar Fuentes Gimeno, Blanca Eulalia García-Pastor, Andrés Gomis González, Maria, 1988- Gómez-Choco, Manuel López-Cancio, Elena Martínez-Sánchez, Patricia Morales, A. Rodríguez-Yáñez, Manuel Segura, Tomás Serena, Joaquín Vivancos-Mora, José Leciñana, María Alonso de Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
author	Palacio-Portilla, Enrique Jesús
author_facet	Palacio-Portilla, Enrique Jesús Roquer, Jaume Amaro, Sergio Arenillas, Juan F. Ayo-Martín, Óscar Castellanos, M. Freijo, María del Mar Fuentes Gimeno, Blanca Eulalia García-Pastor, Andrés Gomis González, Maria, 1988- Gómez-Choco, Manuel López-Cancio, Elena Martínez-Sánchez, Patricia Morales, A. Rodríguez-Yáñez, Manuel Segura, Tomás Serena, Joaquín Vivancos-Mora, José Leciñana, María Alonso de Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
author_role	author
author2	Roquer, Jaume Amaro, Sergio Arenillas, Juan F. Ayo-Martín, Óscar Castellanos, M. Freijo, María del Mar Fuentes Gimeno, Blanca Eulalia García-Pastor, Andrés Gomis González, Maria, 1988- Gómez-Choco, Manuel López-Cancio, Elena Martínez-Sánchez, Patricia Morales, A. Rodríguez-Yáñez, Manuel Segura, Tomás Serena, Joaquín Vivancos-Mora, José Leciñana, María Alonso de Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
author2_role	author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Dislipidemia Dyslipidaemia Estatinas Ictus LDL cholesterol LDL colesterol Prevención Prevention Statins Stroke
topic	Dislipidemia Dyslipidaemia Estatinas Ictus LDL cholesterol LDL colesterol Prevención Prevention Statins Stroke
description	Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia. Development: We performed a systematic review to evaluate the main aspects of the management of dyslipidaemias in primary and secondary stroke prevention and establish a series of recommendations. Conclusions: In primary prevention, the patient's vascular risk should be determined in order to define target values for low-density lipoprotein cholesterol. In secondary prevention after an atherothrombotic stroke, a target value <55 mg/dL is recommended; in non-atherothombotic ischaemic strokes, given the unclear relationship with dyslipidaemia, target value should be established according to the vascular risk group of each patient. In both primary and secondary prevention, statins are the drugs of first choice, and ezetimibe and/or PCSK9 inhibitors may be added in patients not achieving the target value.
publishDate	2022
dc.date.none.fl_str_mv	2022 2022 2022
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/10230/54337 http://dx.doi.org/10.1016/j.nrleng.2020.07.021
url	http://hdl.handle.net/10230/54337 http://dx.doi.org/10.1016/j.nrleng.2020.07.021
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	Neurologia (Engl Ed). 2022 Jan-Feb;37(1):61-72. DOI: 10.1016/j.nrleng.2020.07.021
dc.rights.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf application/pdf
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:Repositorio Digital de la UPF instname:Universitat Pompeu Fabra
instname_str	Universitat Pompeu Fabra
reponame_str	Repositorio Digital de la UPF
collection	Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869403803245084672
score	15.811543

Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

Similares en LA Referencia